Cognitive effects of labeled addictolytic medications.
Fiche publication
Date publication
février 2018
Journal
Progress in neuro-psychopharmacology & biological psychiatry
Auteurs
Membres identifiés du Cancéropôle Est :
Pr TROJAK Benoît
Tous les auteurs :
Pujol CN, Paasche C, Laprevote V, Trojak B, Vidailhet P, Bacon E, Lalanne L
Lien Pubmed
Résumé
Alcohol, tobacco, and illegal drug usage is pervasive throughout the world, and abuse of these substances is a major contributor to the global disease burden. Many pharmacotherapies have been developed over the last 50years to target addictive disorders. While the efficacy of these pharmacotherapies is largely recognized, their cognitive impact is less known. However, all substance abuse disorders are known to promote cognitive disorders like executive dysfunction and memory impairment. These impairments are critical for the maintenance of addictive behaviors and impede cognitive behavioral therapies that are regularly administered in association with pharmacotherapies. It is also unknown if addictolytic medications have an impact on preexisting cognitive disorders, and if this impact is modulated by the indication of prescription, i.e. abstinence, reduction or substitution, or by the specific action of the medication.
Mots clés
Animals, Central Nervous System Agents, adverse effects, Cognition, drug effects, Humans, Substance-Related Disorders, drug therapy
Référence
Prog. Neuropsychopharmacol. Biol. Psychiatry. 2018 Feb 2;81:306-332